If wearables’ announcements were Bingo games with chips for hot topics, Denver-based BioIntellisense just won the evening’s $500 grand prize. The company’s cost-effective, Data-as-as-Service (DaaS) platform’s medical-grade, single-use, BioSticker on-body wearable sensor was FDA-cleared to provide Remote Patient Monitoring (RPM) for continuous vital signs for up to 30 days. (There; I think that checks all the boxes!)
According to Dr. Richard Zene, the University of Colorado School of Medicine’s Chief Innovation Officer and Chair of Emergency Medicine, the BioSticker has potential applications with patients with chronic illnesses before and after hospitalization. The BioSticker measures respiratory rate, heart rate at rest, skin temperature, body position, activity levels, sleep status, high-resolution gait analysis, fall detection, and symptomatic events.
“The use of the BioSticker device for continuous health monitoring enables us to monitor a patient in their home and recognize when a patient may have an exacerbation of illness even before they manifest symptoms,” Zane said. “This may reduce hospitalizations, emergency department visits and shorten hospital stays, creating cost efficiencies for health systems.”
The BioSticker simplifies remote monitoring and early detection with the DaaS platform by capturing vital signs, physical biometrics, and symptomatic events. BioIntellisense analytics will enable clinicians to access high-resolution patient data trending analysis. The timeliness and medical-grade data accuracy further enable high-level care in patients’ homes.
